Aisling Capital Management LP

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 12, 2025), Aisling Capital Management LP reported 14 stock positions worth $456.4 million. Its top holding was Bridgebio Pharma (BBIO) at 69.3% of the portfolio, followed by Verona Pharma (VRNA, 14.4%) and Syndax Pharmaceuticals (SNDX, 4.4%). Compared with Q2 2025, it opened 2 new positions, sold out of 1 and added to 2. The biggest buy was a new position in Bridgebio Oncology Therapeut (BBOT) and the biggest sale an exit from Elevation Oncology (ELEV).

Most Recent 13F
Q2 2026
Location
NEW YORK, NY
CIK
0001766721
Portfolio Value
$456.4M (Q3 2025)
SEC Filing
0001766721-25-000006 ↗ filed Nov 12, 2025

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q1 2024: $295.5M Q1 2024 Q2 2024: $231.1M Q2 2024 Q3 2024: $261.1M Q3 2024 Q4 2024: $281.8M Q4 2024 Q1 2025: $288.5M Q1 2025 Q2 2025: $359.7M Q2 2025 Q3 2025: $456.4M $456.4M Q3 2025 Q4 2025: $478.9M Q4 2025 Q1 2026: $476.3M Q1 2026 Q2 2026: $471.6M Q2 2026

Holdings 14 stocks · $456.4M
BBIO Bridgebio Pharma Inc. 69.29% 6,089,611 $316.3M Add +0.3%
VRNA Verona Pharma Ltd. 14.39% 615,352 $65.7M No change
SNDX Syndax Pharmaceuticals Inc. 4.44% 1,316,806 $20.3M No change
NUVB Nuvation Bio Inc. 2.40% 2,960,659 $11.0M Add +16.5%
GLUE Monte Rosa Therapeutics Inc. 2.39% 1,472,331 $10.9M No change
BCAX Bicara Therapeutics Inc. 1.97% 568,919 $9.0M No change
CMPS Compass Pathways PLC 1.50% 1,198,418 $6.9M No change
BBOT Bridgebio Oncology Therapeut 1.43% 564,625 $6.5M New
BMEA Biomea Fusion Inc. 0.91% 2,048,757 $4.1M No change
SRRK Scholar Rock Holding Corp. 0.63% 77,031 $2.9M New
CALC Calcimedica Inc. 0.35% 521,114 $1.6M No change
ACRS Aclaris Therapeutics Inc. 0.18% 434,455 $825K No change
MRKR Marker Therapeutics Inc. 0.06% 325,370 $290K No change
OKUR Onkure Therapeutics Inc. Class A 0.05% 88,607 $244K No change

Portfolio Sells Q2 2025 → Q3 2025
ELEV Elevation Oncology Inc. Sold out 0.00% −0.29

Portfolio Buys Q2 2025 → Q3 2025
BBOT Bridgebio Oncology Therapeut New 1.43% +1.43
NUVB Nuvation Bio Inc. Add +16.5% 2.40% +1.02
SRRK Scholar Rock Holding Corp. New 0.63% +0.63
BBIO Bridgebio Pharma Inc. Add +0.3% 69.29% −3.56

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 14$471.6MBBIO, GLUE, SNDX, CMPS, BCAX
Q1 2026 13$476.3MBBIO, SNDX, GLUE, BCAX, BBOT
Q4 2025 13$478.9MBBIO, SNDX, GLUE, BCAX, CMPS
Q3 2025 14$456.4MBBIO, VRNA, SNDX, NUVB, GLUE
Q2 2025 13$359.7MBBIO, VRNA, SNDX, GLUE, BCAX
Q1 2025 13$288.5MBBIO, VRNA, SNDX, BCAX, GLUE
Q4 2024 15$281.8MBBIO, VRNA, SNDX, GLUE, PSTX
Q3 2024 16$261.1MBBIO, VRNA, SNDX, BCAX, BMEA
Q2 2024 15$231.1MBBIO, SNDX, VRNA, ELEV, NUVB
Q1 2024 16$295.5MBBIO, SNDX, VRNA, ELEV, BMEA